Iron deficiency is globally prevalent, causing an array of developmental, haematological,
immunological, neurological, and cardiometabolic impairments, and is associated with …

Introduction The treatment landscape of polycythemia vera (PV) has seen major
advancements within the last decade including approval of ruxolitinib in the second line …

We analyzed the neutrophil-to-lymphocyte ratio (NLR) in 1508 patients with PV and found
that those with an NLR≥ 5 were generally older, had a longer disease history, and had …

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by
erythrocytosis in the context of a somatic JAK2 mutation and a hypercellular marrow with …

Objectives Rusfertide is a potent peptide mimetic of hepcidin being investigated for the
treatment of polycythemia vera. This randomized, placebo‐controlled, double‐blind study …

There has been remarkable progress in the development of novel therapeutic approaches
for patients with polycythemia vera (PV). Historically, therapy goals in PV were to mitigate …

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by unregulated red
blood cell production resulting in elevated hemoglobin and/or hematocrit levels. Patients …

Although polycythemia vera (PV) is a chronic and incurable disease, effective management
can allow most patients to maintain functional lives with near-normal life expectancy …

Treatment with rusfertide, an injectable peptide mimetic of the master iron regulatory
hormone hepcidin, essentially eliminated the need for therapeutic phlebotomies in patients …

Hintergrund und Fragestellung: Die Polycythemia vera (PV) ist eine chronische
myeloproliferative Erkrankung, bei der es charakteristischerweise zur Erythrozytose und …